ProofPilot ’s Post

Week 2 of the eCOA March Madness showdown begins... Last weeks matchup breakdown: Medidata Solutions vs Signant Health - A sweep by Medidata, and a bit surprising as Signant is the Number 2 by marketshare, but looks like Medidata took an early lead and maintained its lead well into the second half. Castor vs Clario - The closest competition as many votes for both, but Clario hit a 3-pointer buzzer beater in the last seconds to pull off the victory. Medable, Inc vs. Clinical ink: No surprise here, Medable has a consistent lead through all phases of the game and pulled off a clear victory. YPrime vs Medrio: YPrime's displayed a dominant performance, and has a more sizable competitor this week that will test their offense and defense. This weeks head-to-head games include: Clario vs. Medidata YPrime vs Medable Let the game begin! And don't forget to comment below with your votes. #clinicalresearch #clinicaltrials

Friday afternoon pondering 3 major key takeaways from Asembia 2024: 1) Long standing relationships in the Pharma and Pharma Services Industry are incredibly deep and require thoughtful approaches to support, maintain, leverage, grow. Investment of prioritization, time, execution and follow up critical. Grateful for all the wonderful folks who took time to connect in Vegas. 2) Technology enablement continues to evolve which adds complexity to an already detailed and complex pharmaceutical industry landscape. I was struck by how much effort is required for me to keep current on the pace of industry innovation. 3) The Specialty Pharmacy industry has certainly evolved since my first Armada now Asembia in 2006. And not much has truly changed! Patients have more options for specialty medications and better outcomes all on display this week. #leadership

In #RareDisease #ClinicalTrials, every patient – and every image – matters. Learn why you can trust the far-reaching scientific expertise and extensive experience behind Calyx #MedicalImaging to support these complex and important studies. https://lnkd.in/gntsD3vS #RareDiseaseDay

10 things you may not know about MediMobile. We would love to tell you more about how MediMobile can work for you. Book a Demo on the link below https://lnkd.in/e5eBw7Nv

Curious about LiveView, our very own tool for pathology workflow tracking, only to find in Bergen and nowhere else? 🚀 Read about its development by Patrick Stünkel, Janne Hauglid, and Friedemann Leh. This dynamic dashboard empowers teams to set daily goals and monitor their progress in real-time, fostering motivation, control and a sense of mastery.     Thank you to our team and every single person who has been part of this journey!    Read more about our journey and the impact of LiveView in the article below:   https://lnkd.in/dPh3MXDh      #LiveView #PathologyInnovation #PiVTeam  

Do you even know MedTech?   Prove it 👉 Take the quick Quiz NOW❗   Are you ready to put your knowledge to the test and learn something new? 🚀   Here's a small challenge for your mind 🧠 😃   Let's GO!   Regardless of your level of expertise in medical technology, this quiz will refresh your knowledge, and maybe even surprise you 😳 😃   Enjoy...   #quiz #quizwiz #medicaltechnology #quiztime #knowledgeispower

Learn how the new Oticon Intent™ was developed to address your patients’ challenges to help them engage in life. See the research and development behind this groundbreaking product. Learn more: #OticonIntent #HearingAids

Quick Estimates, Accurate Eligibility with MEDISOFT v28 🚀 MEDISOFT v28 brings you swift patient responsibility estimates and eligibility checks, enhancing care at every step. Customizable estimates and integrated eligibility details make patient interactions smoother than ever. #Microwize #medicalbillingsoftware #MEDISOFTV28 #healthcareproviders #practicemanagement

The point of technology is to enhance your experience of life. At what point does it start to lessen that and begin the road to autonomy? MNGroupZA #change2dominate Claire Rozier Carly Louw Steven Heyns #F1isdead

Hybrid and fully-decentralized trials are all models under the umbrella of DCT. Some models will be a better fit for a protocol than others. But the goals and impact are different: Hybrid approaches reduce burden for patients who are still in proximity of a site. Fully decentralized enable equitable access for all regardless of their location.